Biocon Biologics partners with International Diabetes Foundation

Biocon Biologics Ltd, a biosimilars company and a subsidiary of Biocon Ltd, on Tuesday announced a partnership with the International Diabetes Federation to promote and support IDF's core mission initiative and activities.

Biocon Biologics is the first biosimilar insulin company to partner with the IDF, Bengaluru-headquartered Biocon said in a statement.

The partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin.

Global Head of Market Access & Policy, Biocon Biologics, Alexander Zach, said: "Given our extensive experience in providing affordable insulins globally, we believe we can contribute and support IDF in driving real policy and access actions that will transform lives and diabetes care."

IDFpresident Andrew Boulton said: "For IDF and our partners, the centenary of insulin will provide opportunities to raise awareness of diabetes, promote action to improve access to diabetes care and encourage greater effort to prevent diabetes and its complications."